Evidence map›Paper›PMID 37436797›Full record

ArticleJMIR research protocols2023

Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients (DOPPIO): Protocol for a Prospective Multicenter Study.

Sibylle Mellinghoff, Gero von Gersdorff, Caroline Bruns, Kerstin Albus, Vassiliki Dimitriou, Angela Steinbach, Mathias Schaller, Jörg Janne Vehreschild, Oliver A Cornely, Blasius Janusch Liss

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JMIR research protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03350425 (Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03350425 completednot on this map

Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients

TypeobservationalSponsorUniversity of CologneRan2017 to 2022Enrolled792ConditionsCKD (Chronic Kidney Disease) Stage 5D, Pneumonia
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sibylle Mellinghoff *Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf and Excellence Centre for Medical Mycology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0003-3928-2503
Gero von Gersdorff *Faculty of Medicine and University Hospital Cologne, Department II of Internal Medicine - QiN-group, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-9376-7432
Caroline BrunsCentre for Integrated Oncology Aachen Bonn Cologne Duesseldorf and Excellence Centre for Medical Mycology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0003-4849-2107
Kerstin AlbusCentre for Integrated Oncology Aachen Bonn Cologne Duesseldorf and Excellence Centre for Medical Mycology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0003-1124-4310
Vassiliki DimitriouCentre for Integrated Oncology Aachen Bonn Cologne Duesseldorf and Excellence Centre for Medical Mycology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-4212-7451
Angela SteinbachCentre for Integrated Oncology Aachen Bonn Cologne Duesseldorf and Excellence Centre for Medical Mycology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-7763-8027
Mathias SchallerFaculty of Medicine and University Hospital Cologne, Department II of Internal Medicine - QiN-group, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0009-0002-9526-3411
Jörg Janne VehreschildCentre for Integrated Oncology Aachen Bonn Cologne Duesseldorf and Excellence Centre for Medical Mycology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-5446-7170
Oliver A CornelyCentre for Integrated Oncology Aachen Bonn Cologne Duesseldorf and Excellence Centre for Medical Mycology, Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-9599-3137
Blasius Janusch LissDepartment I of Internal Medicine, Helios University Hospital Wuppertal, Wuppertal, Germany.ORCID https://orcid.org/0000-0002-3551-3450
University of Cologne · DEWitten/Herdecke University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPneumonia is a leading cause of death in patients with end-stage chronic kidney disease treated with dialysis. Current vaccination schedules recommend pneumococcal vaccination. However, this schedule disregards findings of rapid titer decline in adult hemodialysis patients after 12 months.

objectiveThe primary objective is to compare pneumonia rates between recently vaccinated patients and patients vaccinated more than 2 years ago. As an exploratory objective, antipneumococcal antibody titers in hemodialysis patients will be determined as a function. Factors influencing antibody kinetics will be identified.

methodsWithin this prospective multicenter study, we aim to compare 2 strata of vaccinated patients: those recently vaccinated and those vaccinated more than 2 years ago. A total of 792 patients will be enrolled. Twelve partner sites (within the German Centre for Infection Research [DZIF]) with allocated dialysis practices participate in this study. All dialysis patients who are vaccinated against pneumococcal infection in accordance with Robert Koch Institute guidelines prior to enrollment will be eligible. Data on baseline demographics, vaccination history, and underlying disease will be assessed. Pneumococcal antibody titers will be determined at baseline and every 3 months for 2 years. DZIF clinical trial units coordinate titer assessment schedules and actively follow-up on study patients for 2-5 years after enrollment, including validation of end points of hospitalization, pneumonia, and death.

resultsThe study has enrolled 792 patients and the last follow-up has been completed. Currently, the statistical and laboratory analyses are ongoing.

conclusionsResults will increase physician adherence to current recommendations. Establishing a framework for the efficient evaluation of guideline recommendations through a combination of routine and study data will inform the evidence base for future guidelines.

trial registrationClinicalTrials.gov NCT03350425; https://clinicaltrials.gov/ct2/show/NCT03350425. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/45712.

Indexed as

clinical trialcommunicable diseasedialysishemodialysisinfectious diseasekidneypneumococcalpneumoniapulmonaryStreptococcus pneumoniaevaccinationvaccine

Identifiers

PMID37436797
PMCPMC10372763
OpenAlexW4361757264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.